New treatments for cocaine dependence: a focused review
Open Access
- 10 October 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 11 (3), 425-438
- https://doi.org/10.1017/s1461145707008097
Abstract
Cocaine, already a significant drug problem in North and South America, has become a more prominent part of the European drug scene. Cocaine dependence has major somatic, psychological, psychiatric, socio-economic, and legal implications. No specific effective pharmacological treatment exists for cocaine dependence. Recent advances in neurobiology have identified various neuronal mechanisms implicated in cocaine addiction and suggested several promising pharmacological approaches. Data were obtained from Medline, EMBASE, and PsycINFO searches of English-language articles published between 1985 and June 2007 using the key words: cocaine, addiction, cocaine dependence, clinical trials, pharmacotherapy(ies) singly and in combination. Large well-controlled studies with appropriate statistical methods were preferred. Pharmacological agents such as GABA agents (topiramate, tiagabine, baclofen and vigabatrin) and agonist replacement agents (modafinil, disulfiram, methylphenidate) seem to be the most promising in treatment of cocaine dependence. The results from trials of first- and second-generation neuroleptics are largely negative. Aripiprazole, a partial dopaminergic agonist that may modulate the serotonergic system, shows some promise. Preliminary results of human studies with anti-cocaine vaccine, N-acetylcysteine, and ondansetron, are promising, as are several compounds in preclinical development. While no medication has received regulatory approval for the treatment of cocaine dependence, several medications marketed for other indications have shown efficacy in clinical trials. An anti-cocaine vaccine and several compounds in preclinical development have also shown promise. Findings from early clinical trials must be confirmed in larger, less selective patient populations.Keywords
This publication has 101 references indexed in Scilit:
- Safety, tolerability and efficacy of levodopa–carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trialsDrug and Alcohol Dependence, 2007
- Disulfiram effects on responses to intravenous cocaine administrationDrug and Alcohol Dependence, 2007
- Dual dopamine–5-HT releasers: potential treatment agents for cocaine addictionTrends in Pharmacological Sciences, 2006
- Methylphenidate and cocaine: A placebo-controlled drug interaction studyPharmacology Biochemistry and Behavior, 2006
- GABAB Receptor-Positive Modulation Decreases Selective Molecular and Behavioral Effects of CocaineNeuropsychopharmacology, 2006
- Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the ratInternational Journal of Neuropsychopharmacology, 2006
- Pharmacotherapy and other treatments for cocaine abuse and dependenceCurrent Opinion in Psychiatry, 2005
- Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependenceAddiction, 2005
- A POTENTIAL ROLE FOR GABAB AGONISTS IN THE TREATMENT OF PSYCHOSTIMULANT ADDICTIONAlcohol and Alcoholism, 2002
- Baclofen administration for the treatment of affective disorders in alcoholic patientsDrug and Alcohol Dependence, 1993